FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 6 of 34
Jul 30, 2026Amid continued public health concern, the ongoing Ebola outbreak has entered a pivotal phase, but optimism is rising as scientists indicate that a promising vaccine is close to deployment. This development could significantly influence the management of future Ebola crises and demonstrates progress in infectious disease preparedness.
Dr. Priya Nandakumar
Jul 29, 2026In a pivotal move reflecting growing scrutiny of digital health companies, the U.S. Federal Trade Commission (FTC) has taken legal action against Hims & Hers. The agency alleges that the popular telehealth platform engaged in practices that not only misled consumers but also breached their privacy rights. As telemedicine adoption continues to accelerate, this lawsuit could serve as a critical inflection point for industry standards, compliance measures, and consumer trust in digital-first healthcare.
Daniel Cho
Jul 28, 2026Proposed new limits on the duration of visas for international graduate students and postdoctoral researchers are raising alarm bells for the future of U.S. science. Policy experts caution that these restrictions could have lasting repercussions on American competitiveness and innovation.
Michael Torres
Jul 27, 2026In a high-stakes development for the rare disease community and the biopharmaceutical industry, the FDA has publicly disagreed with Capricor’s assertion that its Phase 3 trial for a Duchenne muscular dystrophy (DMD) cell therapy met its primary outcome. As advisory committee deliberations approach, the debate underscores persistent challenges in clinical trial interpretation and the regulatory approval process.
Daniel Cho
Jul 26, 2026Value-based care (VBC) models have shifted the focus of healthcare from sheer volume to demonstrable outcomes, aiming for better efficiency and quality. Yet as rising and unpredictable costs continue to plague the industry, even well-designed VBC initiatives can falter. The delicate balance between lowering expenses and promoting holistic patient care remains one of healthcare’s greatest challenges in 2026.
Dr. Priya Nandakumar
Jul 26, 2026The latest cyclospora outbreak in the United States has brought renewed scrutiny to the balance between nutrition and food safety. Susan Mayne, former director of the FDA Center for Food Safety and Applied Nutrition, argues that systemic reforms are needed to ensure Americans no longer have to choose between eating healthy and preventing foodborne illness.
Dr. Alex Morgan
Jul 25, 2026U.S. drug spending continues to rise, but the benefits remain unevenly distributed, leading to pressing questions about affordability and access. In a recent panel at MedCity News’ Bullseye event, industry experts dissected the ongoing evolution of the prescription drug marketplace, focusing on transparency and accessibility as the next frontiers for improvement.
Jonathan Blake
Jul 25, 2026Unexpected alliances in the U.S. Senate have advanced a bill mandating warning labels for ultra-processed foods and restrictions on junk food advertising—a response to mounting concerns over diet-related diseases and food industry influences. This in-depth report explores the origins, political dynamics, scientific rationale, industry reactions, and the global context driving this major proposed regulation.
Jonathan Blake
Jul 24, 2026The United States has experienced an unprecedented surge in measles cases, topping the record from 2025 and signaling a troubling decline in national vaccination coverage. Public health officials are sounding the alarm, warning that eroding confidence in routine immunizations could set the stage for further outbreaks and setbacks in disease control.
Dr. Alex Morgan
Jul 24, 2026The U.S. Food and Drug Administration’s advisory panel delivered a split decision on the future of peptide compounding by backing Epitalon and rejecting Emideltide. The proceedings exposed divergent perspectives on patient safety, regulatory standards, and the place of unapproved peptides in contemporary medicine.
Dr. Priya Nandakumar
Jul 23, 2026European regulatory authorities have initiated unprecedented action to ensure that the results of clinical trials are publicly accessible, meeting both legal mandates and increasing societal expectations around research transparency. This development is seen by advocacy groups as a transformative moment for the continent’s biomedical sector, signaling new accountability for industry and academia alike.
Emily Carter
Jul 22, 2026Growing job dissatisfaction and uncertainty over healthcare access are converging in the U.S., according to a new study and supplementary reporting. The findings underscore how the nation's healthcare system shapes labor markets, household well-being, and public health, making this a pivotal moment for policymakers and employers to reconsider entrenched benefits structures.
Emily CarterMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.